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Macula densa derived nitric oxide in regulation of glomerular capillary
pressure. Nitric oxide (NO) is produced by enzymes called nitric oxide
synthases (NOS). At least three different isoforms of NOS have been
identified in the kidney. This study examines the effects of selective
inhibition of the inducible isoform (iNOS) and the neuronal isoform
(bNOS) on the glomerular capillary pressure (P0), through studies of the
tubuloglomerular feedback (TGF) mechanism in anaesthetized rats. The
proximal tubular stop-flow pressure (Ps) was measured to estimate
changes in P0 obtained after activation of the TGF system by varying the
loop of Henle perfusion rate with artificial ultrafiltrate including vehicle,
NOS inhibition or L-arginine. Infusion of nonspecific NOS inhibition
(N'°-Nitro-L-arginine) increased maximal TGF responses (PsF) by 84%
and L-arginine decreased SF by 37%. Aminoguanidine, a selective
iNOS-inhibitor, failed to increase whereas the nonspecific NOS
inhibitor methylguanidine increased zP5 by 64%. 7-Nitro indazole
(7-NI), a selective bNOS inhibitor, increased SF by 57% when infused
intratubularly, and intraperitoneal administration of 7-NI increased SF
by 78%, without any change in blood pressure. Since bNOS is exclusively
located in the macula densa (MD) cells, these results confirm and
strengthen the obligatory role of MD-produced NO in regulation of TGF
and P0 which has been suggested earlier. iNOS, widely expressed in the
kidney, does not seem to play any important role in regulation of P0g.
Production of nitric oxide (NO) from L-arginine (L-Arg) is
mediated by enzymes called nitric oxide synthases (NOS). At least
three different isoforms of this enzyme have been identified in the
mammalian body. All three isoforms are present in the kidney and
their specific localization has recently been reviewed [1]. Two
NOS isoforms are constitutively expressed: (1) endothelial NOS
(eNOS), which is located in the cytoplasm of endothelial cells in
renal vessels, and (2) the neuronal isoform of NOS, which was first
identified in brain tissue and was therefore called brain NOS
(bNOS). The latter has been found to be located in the macula
densa (MD) cells of the juxtaglomerular apparatus [2—4]. How-
ever, a more recent study demonstrated that the efferent arteriole
of mammalian kidneys contain both eNOS and bNOS [5j. The
third type of NOS, the inducible NOS (iNOS), has been found in
a wide range of renal structures. Glomerular, proximal tubular,
distal convoluted and mesangial cells have all been shown to
contain iNOS [6, 71. Furthermore, iNOS has been identified in
endothelial cells of renal vessels, mainly in preglomerular arteries
[81. Although the effects of general NO inhibition by structural
analogues of L-Arg have been thoroughly investigated, very little
is known about the physiological importance of NO produced
specifically by the different isoforms.
Wilcox and coworkers [4] proposed a role for MD-produced
NO in regulation of the glomerular filtration pressure. We
recently showed that intratubular injections of L-NNA altered the
sensitivity of the tubuloglomerular feedback (TGF) mechanism
and potently increased the TGF-mediated vasoconstriction of the
afferent arteriole [9]. In studies of the early proximal flow rate
(EPFR), we also found that the single nephron glomerular
filtration rate (SNGFR) was only affected by NOS inhibition when
TGF was activated. Ito and Ren [101 have shown that TGF-
mediated constriction of microperfused afferent arterioles from
rabbit kidneys is enhanced by NOS inhibition. This finding
suggests that MD-produced NO modulates the tonus in the
afferent arteriole. However, since all studies on renal hemody-
namics performed thus far have been carried out using nonspecific
NOS inhibitors, it is difficult to determine which isoform or
isoforms are involved in the physiological mechanisms investi-
gated.
Some recent reports have provided clear evidence for the
existence of more specific NOS inhibitors. Aminoguanidine has
been shown to selectively inhibit iNOS, while the closely related
guanidino compound methylguanidine is a nonspecific NOS in-
hibitor [11, 121. Even more interestingly, Moore et al have
reported that 7-nitro indazole (7-NI) selectively inhibits bNOS
[13, 141 and that in in vivo experiments this drug had no effect on
arterial blood pressure (PA). The purpose of this study was to
verify our assumption that TGF-mediated changes in glomerular
capillary pressure (0) are counterbalanced by MD-derived NO.
The proximal tubular stop-flow pressure technique was used to
study changes in GC, obtained by activation of TGF, by varying
the loop of Henle perfusion rate. The TGF characteristics were
determined after intratubular or intraperitoneal (7-NI only) ad-
ministration of the different types of selective NOS inhibitors and
L-Arg. Our results clearly demonstrate that the earlier reported
effects of NOS inhibition on the TGF mechanism are predomi-
nately caused by the blockade of bNOS in the macula densa cells.
Methods
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Experiments were carried out on adult male Sprague-Dawley
rats (Møllegaard, Copenhagen, Denmark) weighing 210 to 300 g.
The animals were given free access to food and tap water until the
day before an experiment. They were fasted overnight but had
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free access to a sugar solution (5% glucose in tap water). On the
day of the experiment, the rats were anesthetized by an intraper-
itoneal injection of Thiopenthal sodium (TrapanalR, 120 mg/kg1
body wt), which was supplemented as necessary during the
experiment. Their body temperatures were maintained at 37.5°C
by placing the animals on a servo-regulated heating pad with
registration of the temperature through a rectal probe. A trache-
ostomy catheter was inserted to allow for spontaneous breathing.
Catheters were inserted into the carotid artery and the jugular
vein for arterial blood pressure measurements and infusion of
maintenance fluid (saline, 0.9% NaCI; 10 mI/hr/kg body wt). The
bladder was cannulated for urine release. Through a subcostal
flank incision, the left kidney was exposed. The kidney was
dissected free from surrounding tissue, placed in a lucite cup and
fixed with a 3% agar-agar solution. The kidney surface was
covered with mineral oil to prevent drying. After an equilibration
time of 50 minutes, micropuncture measurements were started.
Stop-flow pressure measurements
TGF characteristics were determined using the stop-flow tech-
nique. Under a stereo microscope, randomly chosen proximal
tubular segments on the kidney surface were punctured with a
sharpened glass pipette (outer diameter [O.D.j 3 to 5 jxm) filled
with a stained (Lissamine green) I M NaC! solution. The pipette
was connected to a servo-nulling pressure system (WP Instru-
ments, New Haven, CT, USA) to determine the proximal tubular
free-flow pressure (PT). By injections of the stained fluid, the
tubular distribution on the kidney surface was defined. In
nephrons where more than three proximal segments were identi-
fied, a second pipette (O.D. 7 to 9 xm) was inserted in the last
accessible segment of the proximal tubule. This pipette was filled
with an artificial ultrafiltrate (140 mM NaCl, 5 mat KCI, 2 mM
CaCl2, 1 mat MgC12, 4 mat NaHCO3, 7 mat urea, 2 g/liter
Lissamine green, pH 7.4), and connected to a microperfusion
pump (Hampel, Frankfurt, Germany). Between these two pipettes
a solid wax block was placed, with a third pipette (O.D. 7 to 9 jm).
The pressure upstream to the block, the stop-flow pressure
(PSF), was measured at different perfusion rates (0 to 40 nl/min)
in the ioop of Henle. The flow was increased or decreased in steps
of 2.5 to 5 nI/mm and the maximal feedback response SF was
determined as the decrease in SF at the 40 nl/min perfusion rate,
compared with SF at zero perfusion. The tubular flow rate at
which 50% of the maximal pressure response was obtained, called
the turning point (TP), was determined; by definition TP is a
measure of the TGF sensitivity.
Series I
The first series of experiments (6 rats, 11 nephrons) was
designed to study the time-dependent effect of intratubularly
administered NOS inhibition on the maximal TGF response.
While SF was being recorded, the loop of Henle perfusion rate
was increased from 10 to 40 nI/mm for two minutes every fifth
minute during a period of 20 minutes. Blockade of NOS was
achieved by changing the perfusion pipette to one containing
N°'-Nitro-L-arginine (L-NNA) at iO M dissolved in the ordinary
perfusion solution. This concentration was chosen for the reason
that in a former study we had found a maximal effect of L-NNA
on TGF at a concentration of iO— M [9].
Series II
The second series of experiments was conducted to examine the
effect of L-Arg (Sigma Chemical Co., St. Louis, MO, USA) on SF
and TGF. After having determined the TGF characteristics
during control conditions, L-Arg infusion was accomplished by
changing the perfusion pipette to a similar pipette containing
L-Arg at a concentration of 10—2 M. When the L-Arg measure-
ments were done, NOS blockade were achieved by changing to a
pipette containing L-NNA at iO M. The TGF characteristics
were determined 15 minutes after administration of the drugs (the
loop of Henle was perfused for 15 mm at a low, 10 nl/min,
non-TGF-activating perfusion rate), since this is the time needed
to get a full inhibitory effect on NO production. Once induced, the
effect of L-NNA is long lasting, and it is possible to turn off the
perfusion system and measure SF in nonperfused nephrons.
Series III
A third series of experiments was carried out to examine the
effect of the iNOS-selective NOS inhibitor aminoguanidine (Sig-
ma Chemical) on TGF. The results were compared with those
obtained with the closely related guanidino compound methylgua-
nidine (Sigma Chemical), which is known to be a nonspecific NOS
inhibitor. The substances were administered in a concentration of
iO M using the same protocol as described above. Like in series
II, the experiments were completed by changing the perfusion
pipette to a third pipette containing L-NNA, to study the maximal
effect of total NOS inhibition.
Series IV
In the fourth series, bNOS was selectively inhibited with 7-NI
(Research Biochemicals International, MA, USA), using the same
technique as in series III. Since it was impossible to totally dissolve
this substance in ordinary perfusion solution at a concentration of
i03 M (the concentration used was approximately 5 x iO M),
the experiments were repeated after intraperitoneal administra-
tion of the drug (25 mg/kg bw dissolved in heated (80°C) peanut
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Fig. 1. Maximum change in proximal tubular stop-flow pressure (.P1.) in
control nephrons (LI) and during L-NNA infusion (Vi) at different times of
loop perfusion. *D < 0.05 compared with control. tP < 0.05 compared with
L-NNA at five minutes. tIP < 0.05 compared with L-NNA at 10 minutes.
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Table 1. Tubuloglomerular feedback characteristics in control
situations and after NO-synthesis stimulation with intratubular infusion
of L-arginine (L-ARG) and L-NNA
Control L-ARG L-NNA
PAmmHg 121±4 122±4 122±4
mm Hg 13.8 0.6 13.8 0.6 13.8 0.7
SF mm Hg 43.6 1.8 43.0 1.6 42.7 1.5
sF mm Hg 10.9 0.7 6.8 0.7a 18.4 2.5a5SF % 25.0 1.3 15.7 1.6 43.1 5.6
TP nI/mm 20.1 1.0 19.5 1.4 17.2 0.8'
mm 5/8 5/8 5/7
Values are given as mean SE. Abbreviations are: A' mean arterial
pressure; T' proximal tubular pressure; PSF' proximal tubular stop-flow
pressure; maximal stop-flow pressure response; TP, turning point;
m, animals; n, nephrons.
P < 0.05 compared with control
h P < 0.05 compared with L-ARG
oil (Sigma Chemical). The series IV experiments were not ended
by L-NNA infusion.
Statistical analyses
All values are given as mean SE. Student's t-test for unpaired
observations was used for statistical analysis in series I. When
multiple groups were compared, one-way analysis of variance
(ANOVA) was used. To allow for more than one comparison with
the same variable, the Bonferroni method was employed. This
states a significance level of P/M, where M is the number of
comparisons to be made. A P value less than 0.05 was accepted for
significance.
Results
Series I
Figure 1 shows the time-dependent effect of L-NNA on LPSF.
Five minutes after administration of the intratubular NOS block-
ade, iPSF was significantly increased in L-NNA infused nephrons
compared to nephrons perfused with ordinary perfusion solution
Table 2. Tubuloglomerular feedback characteristics in control
situations and after NO-synthesis blockade with the iNOS selective
inhibitor aminoguanidine (AG) and with L-NNA
Control AG L-NNA
PmmHg 123±4 123±4 123±4
mm Hg 13.9 0.4 13.9 0.4 13.9 0.4
SF mm Hg
5F mm HgSF %
TP nI/mm
45.7 1.3
10.5 1.0
23.0 1.9
21.4 0.5
45.4 1.3
9.7 0.9
21.3 1.8
20.5 0.5
43.7 1.5'
19.4 2.4'
44.3 5.4'
16.9 OSab
mm 7/12 7/12 7/12
Values are given as mean su. Abbreviations are: A' mean arterial
pressure; T, proximal tubular pressure; SF, proximal tubular stop-flow
pressure; zP5, maximal stop-flow pressure response; TP, turning point;
m, animals; n, nephrons.
a P < 0.05 compared with control
h P < 0.05 compared with AG
Table 3. Tubuloglomerular feedback characteristics in control
situations and after NO-synthesis blockade with methylguanidine (MG)
and L-NNA
Control MG L-NNA
117±2 117±2PmmHg 117±2
mm Hg 14.0 0.3 14.0 0.3 14.0 0.3
mm Hg
LXPSF mm Hg
43.2 1.4
8.8 1.2
43.0 1.4
14.4 1.6'
42.6 1.5
17.6 2.5"
SF % 20.5 3.0 34.1 47a 41.3 4.2'
TP nI/mm 20.4 0.8 17.0 1.6 16.5 o.sa
m/n 6/8 6/8 6/8
Values are given as mean SE. Abbreviations are: A, mean arterial
pressure; T, proximal tubular pressure; PSF proximal tubular stop-flow
pressure; iPs, maximal stop-flow pressure response; TP, turning point;
m, animals; n, nephrons.
a P < 0.05 compared with control
"P < 0.05 compared with MG
(11.7 0.9 vs. 8.7 0.6 mm Hg). During the first 15 minutes,
SF continued to increase in L-NNA treated nephrons, but was
unchanged in control nephrons. After 10 minutes SF was
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Fig. 2. A. Proximal tubular stop-flow pressure (P5k) at different peifusion rates, under control conditions and during treatment with L-argmnine (L-ARG) and
L-NNA. < 0.05 compared with control. B. Turning point (TP) in each individual nephron in controls and during L-ARG administration. Dotted line
represents mean value.
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increased to 14.8 1.2 and a full effect (20.1 1.5 mm Hg) was
reached five minutes later.
Series II
The effect of intratubular L-Arg and L-NNA infusion is illus-
trated in Table 1 and Figure 2. Neither A nor T was affected by
intratubular administration of any of the drugs used in this study.
sF in control experiments was 43.6 1.8 mm Hg and was not
influenced by L-Arg (43.0 1.6 mm Hg). Activation of TUF by
increasing the ioop of Henle perfusion rate decreased SF to 32.7
mm Hg (PsF = 10.9 mm Hg) in control nephrons. The fall in SF
was significantly abated to 36.2 1.7 (sF = 6.8 mm Hg) after
TGF activation with additional L-Arg infusion. TP, however, was
not affected by L-Arg. Subsequent L-NNA infusion did not affect
SF at low loop of Henle perfusion rate, but after maximal
activation of TGF (40 nl/min) P was decreased to 24.3 0.7 mm
Hg (PsF = 18.4 mm Hg). In addition, TP was decreased from
19.5 1.4 to 17.2 0.8 nI/mm.
Series III
The influence of intratubular infusion of aminoguanidine and
methylguanidine on the TGF mechanism is summarized in Tables
2 and 3 and Figures 3 and 4. Infusion of the iNOS selective NOS
inhibitor, aminoguanidine, did not affect either nsF, SF or TP.
L-NNA infusion following aminoguanidine administration led to
a twofold increase in IPSF (9.7 vs. 19.4 mm Hg) and resetting of
TP from 20.5 to 16.9 nl/min. Infusion of the unspecific NOS
inhibitor methylguanidine resulted in an increase in 'SF from 8.8
to 14.4 mm Hg, which was further increased by L-NNA to 17.6
mm Hg. In addition, TP was decreased by methylguanidine from
20.4 to 17.0 nl/min. Subsequent L-NNA administration did not
further decrease TP.
Series IV
Table 4 and Figures 5 and 6 show the effects of the bNOS (MD)
selective inhibition by 7-NI on the TGF characteristics. Intratu-
bular infusion of 7-NI did not alter SF (39.6 1.2 mm Hg),
although the TGF response was markedly enhanced. SF was
significantly increased from 9.3 to 14.6 mm Hg. However, the
change in TP from 18.1 to 16.9 nl/min was not significant.
Intraperitoneal infusion of 7-NI did not alter A, T or SF, but
resulted in an increase in TGF responsiveness similar to that seen
after intratubular administration. zPSF was increased from 8.3 to
14.7 mm Hg. Furthermore, intraperitoneal administration reset
the TGF sensitivity (TP was decreased from 18.2 to 14.2 nl/min) to
the same extent as did L-NNA. Intraperitoneal administration of
peanut oil without 7-NI did not affect the TGF characteristics.
As can be seen in Tables 1 to 4, there is a substantial variation
in SF to NOS inhibition between the different series of exper-
iments. However, in our studies the magnitude of SF is depen-
dent on the sF at zero perfusion and, the magnitude of zP
after NO inhibition is very much dependent on the magnitude of
SF in the control experiments that always precedes drug
administration. For this reason LPSF is divided by SF at zero
perfusion and presented in the tables as SF %.Thevariations in
sF % is evidently much smaller.
Discussion
The present studies were designed to investigate the impor-
tance of MD-produced NO in the regulation of P0 and TGF.
Four principal objectives were addressed to determine: (a)
whether or not the effect of intratubular NOS blockade is
time-dependent; (b) if intratubular administration of L-Arg can
stimulate NO production from the MD cells; (c) whether or not
iNOS-derived NO is involved in control of the tonus of the
afferent arteriole; and (d) if 7-NI, a bNOS-selective inhibitor, is a
potent blocker of MD-produced NO and its effect on TGF
sensitivity.
We recently reported that both systemic and intratubular NOS
inhibition led to powerful increases in TUF sensitivity and reac-
tivity [91. Moreover, measurements of the early proximal flow rate
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Fig. 3. A. Proximal tubular stop-flow pressure (PSF) at different perfusion rates, under control conditions and during treatment with aminoguanidine(Aminog.) and L-NNA. *p < 0.05 compared with control. B. Turning point (TP) in each individual nephron in controls and during aminoguanidine
administration. Dotted line represents mean value.
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Fig. 4. A. Proximal tubular stop-flow pressure (PSF) at different perfusion rates, under control conditions and during treatment with methylguanidine
(Methyig.) and L-NNA. *f < 0.05 compared with control. B. Turning point (TP) in each individual nephron in controls and during methylguanidine
administration. Dotted line represents mean value. *p < 0.05 compared with control.
Table 4. Tubuloglomerular feedback characteristics in control
situations and after NO-synthesis blockade with intraperitoneal and
intratubular infusions of the bNOS selective inhibitor 7-Nitro indazole
(7-NI)
Intratubular
administration
Intraperitoneal
administration
Control 7-NI Control 7-NI
PAmmHg 122±3 122±3 123±2 122±2
mm Hg 13.7 0.6 13.7 0.6 12.9 0.6 12.9 0.6
SF mm Hg 39.6 1.2 39.6 1.2 41.3 2.3 42.0 2.2
APSF mm Hg 9.3 1.2 14.6 1.5k' 8.3 1.1 14.7 iF'SF % 24.3 3.6 37.6 44a 20.0 2.4 36.2 3.6a
TP nI/mm 18.1 0.7 16.9 1.1 18.2 1.2 14.2 1.5"
rn/n 6/11 6/11 7/7 7/7
Values are given as mean SE. Abbreviations are: A, mean arterial
pressure; T, proximal tubular pressure; SF, proximal tubular stop-flow
pressure; maximal stop-flow pressure response; TP, turning point;
m, animals; n, nephrons.
a P < 0.05 compared with control in each group
indicated a more potent decrease in SNGFR when the flow in the
loop of Henle was increased from 10 to 40 nI/mm during
intratubular NOS inhibition. This indicates that NO only affects
sF when the TGF mechanism is activated. All previous experi-
ments were performed 15 minutes after administration of the
nonspecific NOS inhibitor L-NNA. The interval of 15 minutes was
chosen since this is the time needed to get a maximal effect on A
after systemic blockade of NOS. The first series of experiments
was conducted to examine the question of whether or not the
effect of intratubular NOS blockade is also conditioned by the
time. Our results clearly demonstrate that a full effect of L-NNA
is not attained until 15 minutes after introduction of the drug,
which is in accordance with our previous report [9]. Longer
periods of L-NNA infusion did not further strengthen the effect of
L-NNA. In a very recent study [15] administration of NGL
arginine (NLA) into the proximal tubule of one nephron mark-
edly increased the TGF response of the studied neighboring
nephron. When the nephron under study was perfused with NLA
dissolved in mannitol, the effects on TGF were blunted. Taken
together, this indicates that tubular reabsorption of the inhibitor
is essential for the full expression of the effect on TGF respon-
siveness.
The kidney is known to be a major producer of arginine [16]
and the synthesis seems to be located in the proximal convoluted
tubule [17]. It is not unlikely that arginine produced in the cells of
the proximal tubule serves as a substrate for local NO production
in regions that can be reached by tubular transport. The series II
experiments were performed to study the effect of perfusing the
loop of Henle with an artificial ultrafiltrate containing a high
concentration of L-Arg. Loop of Henle perfusion at a low rate
with L-Arg added to the ultrafiltrate did not affect SF, but when
the perfusion rate was increased to 40 nI/mm, co-perfusion of
L-Arg resulted in a significant decrease in the TGF response. This
indicates that an increased tubular concentration of L-Arg can
stimulate NOS in the MD cells to produce more NO and thereby
influence the tonus in the afferent arteriole. It is not known,
however, if the production of L-Arg in proximal tubular cells can
reach such high concentrations.
As discussed earlier, intratubular infusion of an unspecific NOS
inhibitor (L-NNA) led to very potent reductions in SF only when
the ioop of Henle was perfused at a high (TGF activating)
perfusion rate [9]. This finding was very much in line with an
earlier observation by Ito and Ren [10]. By microperfusion of an
isolated rabbit juxtaglomerular apparatus, these authors found an
increased afferent arteriolar constriction as a response to high
NaCI solution when the MD cells were co-perfused with unspe-
cific NOS inhibition (L-NAME). Taken together, this indicates
that NO produced in other regions than the endothelium is
involved in regulation of the tonus of the afferent arteriole, and
since previous studies had shown that the MD cells contain bNOS
[2—4], it has been suggested that the MD cells are responsible for
this NO production. However, more recent studies have shown
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the presence of iNOS in different parts of the nephron as well as
in the afferent arteriole [6, 7, 14, 15], thus indicating a more
complex system for intrarenal NO synthesis. The series III
experiments were therefore conducted to investigate the role of
iNOS in regulation of P. Some recent studies have demon-
strated that aminoguanidine is a selective inhibitor of iNOS,
whereas the very closely related guanidino compound methylgua-
nidine is a nonselective NOS inhibitor, although not as potent as
the normally used L-Arg analogues [11, 12, 16]. In the present
study neither of the two guanidino compounds affected SF when
perfusion of the loop of Henle was kept at a low rate. TGF
activation decreased SF, but was not influenced by coinfusion of
aminoguanidine. Infusion of L-NNA into the same nephron
resulted in a potent increase in TGF sensitivity. Methylguanidine,
on the other hand, significantly enhanced the TGF response and
in addition decreased TP, but not as potently as did L-NNA.
These results indicate that iNOS-derived NO has little or no
influence on the regulation of P under normal conditions. The
presence of iNOS both in glomerular and tubular cells, however,
indicates that this isoform may be of great importance under
pathological conditions such as diabetes [18, 19] and other
situations where the NO synthesis is increased.
The experiments in series IV were conducted to examine the
effects of the selective bNOS inhibitor 7-NI, a compound that has
been shown to block bNOS without altering A [13, 141 or total
renal blood flow [20]. In our experiments, intratubularly infused
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Fig. 5. A. Proximal tubular stop-flow pressure (P5) at different perfusion rates under control conditions and during intratubular (IT) administration of 7-nitro
indazole (7-NI). Results from L-NNA treated nephrons are inserted for comparison. *p < 0.05 compared with control. B. Turning point (TP) in each
individual nephron in controls and during 7-NI administration. Dotted line represents mean value.
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Fig. 6. A. Proximal tubular stop-flow pressure (P5F) at different perfusion rates, under control conditions and during intraperitoneal (i.p.) administration of
7-nitro indazole (7-NI). Results from L-NNA treated nephrons are inserted for comparison. *p < 0.05 compared with control. B. Turning point (TP)
in each individual nephron in controls and during 7-NI administration. Dotted line represents mean value. p < 0.05 compared with control.
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7-NI was as potent as L-NNA in increasing zPSF, but did not
significantly reduce TP. Since it was impossible to completely
dissolve 7-NI in ordinary perfusion solution at a concentration of
i0 M (Methods), TGF was also characterized after intraperito-
neal administration of 7-NI dissolved in peanut oil, and this mode
of administration led to a TGF resetting equivalent to that
observed after intratubular infusion of L-NNA. None of the other
studied parameters were affected by this drug. The marked
increase in sF combined with a decrease in TP indicates an
increased TGF sensitivity and demonstrates that the TGF reset-
ting normally seen after unselective NOS inhibition is predomi-
nantly caused by blocking of bNOS in the MD cells. Still, the
feasible involvement of eNOS localized in the endothelium of the
arterioles cannot completely be excluded.
The major functions of the MD cells are: (1) to control the
glomerular filtration rate through the TGF mechanism, and (2) to
mediate renin release from the granular cells in the afferent
arteriole. The results of this study demonstrate an obligatory role
of MD-derived NO in counteracting the TGF-mediated vasocon-
striction of the afferent arteriole, and thereby also in the control
of PGC. The actual effect of NO on renin release, on the other
hand, is still under debate. Interestingly, it was recently reported
that inhibition of MD NOS by 7-NI did not influence renin
release, and the author concluded that MD-derived NO is not a
regulator of renin production [20]. On the other hand, studies on
renin release from an isolated perfused juxtaglomerular apparatus
indicated that NO might both stimulate and inhibit renin release
[211. The effect depended very much on the side effects of drug
application, indicating that eNOS-derived NO may inhibit renin
release while MD-derived NO may stimulate renin release. An-
other possible target for MD-derived NO could be the mesangial
cells of the glomeruli. The contractility of these cells might be
under strong influence of MD-produced NO, thus giving the MD
cells an interesting role to play in modulating the ultrafiltration
coefficient, and thereby implying another way of modulating GFR.
In conclusion, the present study demonstrates that 7-NI is a
potent inhibitor of macula densa NOS (bNOS) in vivo. The fact
that 7-NI treatment results in an increase in TGF sensitivity
similar to that previously reported after unselective NOS inhibi-
tion points to a very special role of MD-derived NO in the
regulation of P0c. Loop of Henle perfusion with the addition of
L-Arg decreased the maximal TGF response, indicating that
increased intratubular concentrations of L-Arg might stimulate
MD production of NO and thereby counterbalance the TGF-
mediated vasoconstriction. The finding that MD perfusion with
the iNOS-selective inhibitor aminoguanidine did not affect either
SF or the TGF responsiveness indicates that iNOS-derived NO is
of little importance for regulation of P0c, at least under normal
conditions.
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